NCT05615038

Brief Summary

Compare the effectiveness and safety of contact aspiration (CA) and stent retriever (SR) in acute ischemic stroke patients with basilar artery occlusion.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
338

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2022

Typical duration for not_applicable

Geographic Reach
1 country

6 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 7, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

November 7, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 14, 2022

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 21, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

April 27, 2025

Status Verified

February 1, 2025

Enrollment Period

2.3 years

First QC Date

November 7, 2022

Last Update Submit

April 24, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Rate of first pass effect (FPE)

    \[The definition of FPE: 1) single pass/use of the device; 2)recanalization of the large vessel occlusion to eTICI 2C/3;3) no use of rescue therapy.\]

    24 hours

Secondary Outcomes (15)

  • Rate of complete reperfusion (eTICI 3) after first-line thrombectomy strategy and at the end of endovascular procedure

    24 hours

  • Rate of near to complete reperfusion (eTICI 2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure

    24 hours

  • Rate of successful reperfusion (eTICI 2b/2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure

    24 hours

  • Rate of Arterial Occlusive Lesion (AOL) recanalization score 3 after first-line thrombectomy strategy and at the end of endovascular procedure

    24 hours

  • Groin puncture time to successful reperfusion time (min)

    24 hours

  • +10 more secondary outcomes

Study Arms (2)

Contact aspiration first line thrombectomy

EXPERIMENTAL

Patients will have the mechanical thrombectomy by first-line contact aspiration

Procedure: Contact aspiration Thrombectomy

Stent retriever first line thrombectomy

ACTIVE COMPARATOR

Patients will have the mechanical thrombectomy by first-line stent retriever

Procedure: Stent retriever thrombectomy

Interventions

Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.

Contact aspiration first line thrombectomy

Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.

Stent retriever first line thrombectomy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age≥18 years;
  • Acute basilar artery occlusion confirmed by CTA/MRA/DSA;
  • Last known well to puncture time≤24 hours;
  • pc-ASPECTS score≥6 points;
  • Baseline NIHSS score≥10 points;
  • Consent to endovascular treatment;
  • Informed consent signed.

You may not qualify if:

  • Baseline mRS≥3 points;
  • Known or suspected severe basilar artery stenosis (\>70%) or chronic occlusion based on history, imaging, or clinical manifestations;
  • Refractory hypertension that is difficult to be controlled by drugs (defined as persistent systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg)
  • Genetic or acquired hemorrhagic tendency, coagulation factor deficiency or on anticoagulant therapy and International Normalized Ratio (INR) \> 3.0;
  • Laboratory tests: baseline blood glucose \<50mg/dl (2.8mmol/L) or \>400mg/dl (22.2mmol/L); Baseline platelet count \<50×109/L;
  • Known severe allergy (more severe than skin rash) to contrast agents uncontrolled by medications;
  • Females who are pregnant, or those of childbearing, potential with positive urine or serum beta Human Chorionic Gonadotropin test;
  • Other circumstances that the investigator considers inappropriate for participation in the trial or that may pose significant risks to patients (such as inability to understand and/or follow the study procedures and/or follow up due to mental disorders, cognitive or emotional disorders).
  • CT or MR evidence of acute intracranial hemorrhage (the presence of microbleeds on MRI is allowed);
  • Midline shift or herniation, mass effect with effacement of the ventricles;
  • Complete cerebellar infarct on CT or MRI with significant mass effect and compression of the 4-th ventricle;
  • Complete bilateral thalamic infarction on CT or MRI;
  • Inability to endovascular treatment due to Excessive tortuosity, variation, or dissection of the artery;
  • Subjects with occlusions in both intracranial vertebral arteries;
  • Subjects with occlusions in both anterior and posterior circulation;
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Location

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China

Location

Beijing Daxing District People's Hospital

Beijing, Beijing Municipality, China

Location

Anyang People's Hospital

Anyang, Henan, China

Location

Zhangzhou Municipal Hospital

Zhangzhou, Henan, China

Location

Baotou Center Hospital

Baotou, Neimenggu, China

Location

Related Publications (1)

  • Xuan S, Yang M, Sun D, Song L, Gao F, Mo D, Ma N, Pan Y, Liu L, Zhao X, Wang Y, Wang Y, Nogueira R, Miao Z. Contact aspiration versus stent retriever thrombectomy for acute basilar artery occlusion (ANGEL-COAST): rationale and design of a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Stroke Vasc Neurol. 2025 Oct 28:svn-2025-004232. doi: 10.1136/svn-2025-004232. Online ahead of print.

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Interventional Neurology

Study Record Dates

First Submitted

November 7, 2022

First Posted

November 14, 2022

Study Start

November 7, 2022

Primary Completion

February 21, 2025

Study Completion

June 30, 2025

Last Updated

April 27, 2025

Record last verified: 2025-02

Locations